Biological activity of mutants of human tumour necrosis factor-alpha (original) (raw)

. 1992 Jul;76(3):433–438.

Abstract

Point mutations in different regions of the tumour necrosis factor-alpha (TNF-alpha) molecule influence anti-tumour cytotoxic/cytostatic activities as well as haemorrhagic tumour necrosis, tumour regression and lethal toxicity in mice. Mutations in the C-terminal region in positions 150 and 155 markedly decrease cytotoxicity for murine L929 fibroblasts and human MCF7 mammary carcinoma cells. Competitive binding experiments with 125I-labelled TNF-alpha revealed that the loss of cytotoxicity is caused by a loss of target cell binding. In contrast to the reduced activity against L929 and MCF7 cells, neither binding to nor cytostatic activity against the human myeloid leukaemia cell lines HL60 and U937 are affected. This target cell type-dependent behaviour is probably due to the fact that L929 and MCF7 cells express different types of TNF receptor compared with myeloid leukaemia cells. While a mutation in position 127 decreases the overall activity of TNF-alpha, a deletion of four N-terminal amino acids does not reduce biological activity. In vivo the TNF mutants differed in their anti-tumour effects and lethal toxicity, but a segregation of anti-tumour activity and toxicity was not observed.

433

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B., Cerami A. The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol. 1989;7:625–655. doi: 10.1146/annurev.iy.07.040189.003205. [DOI] [PubMed] [Google Scholar]
  2. Brockhaus M., Schoenfeld H. J., Schlaeger E. J., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3127–3131. doi: 10.1073/pnas.87.8.3127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Creasey A. A., Doyle L. V., Reynolds M. T., Jung T., Lin L. S., Vitt C. R. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res. 1987 Jan 1;47(1):145–149. [PubMed] [Google Scholar]
  5. Eck M. J., Sprang S. R. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem. 1989 Oct 15;264(29):17595–17605. doi: 10.2210/pdb1tnf/pdb. [DOI] [PubMed] [Google Scholar]
  6. Fraker P. J., Speck J. C., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978 Feb 28;80(4):849–857. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  7. Gase K., Korobko V. G., Wisniewski H. G., Le J., Dobrynin V. N., Filippov S. A., Gutsche W., Maksimova Y. N., Schlott B., Shingarova L. N. Critical role of the C-terminus in the biological activities of human tumour necrosis factor-alpha. Immunology. 1990 Nov;71(3):368–371. [PMC free article] [PubMed] [Google Scholar]
  8. Gatanaga T., Noguchi K., Tanabe Y., Inagawa H., Soma G., Mizuno D. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-alpha in vivo. J Biol Response Mod. 1989 Jun;8(3):278–286. [PubMed] [Google Scholar]
  9. Gray P. W., Aggarwal B. B., Benton C. V., Bringman T. S., Henzel W. J., Jarrett J. A., Leung D. W., Moffat B., Ng P., Svedersky L. P. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature. 1984 Dec 20;312(5996):721–724. doi: 10.1038/312721a0. [DOI] [PubMed] [Google Scholar]
  10. Hohmann H. P., Remy R., Brockhaus M., van Loon A. P. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem. 1989 Sep 5;264(25):14927–14934. [PubMed] [Google Scholar]
  11. Jones E. Y., Stuart D. I., Walker N. P. Structure of tumour necrosis factor. Nature. 1989 Mar 16;338(6212):225–228. doi: 10.1038/338225a0. [DOI] [PubMed] [Google Scholar]
  12. Kawakami M., Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med. 1981 Sep 1;154(3):631–639. doi: 10.1084/jem.154.3.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Klebanoff S. J., Vadas M. A., Harlan J. M., Sparks L. H., Gamble J. R., Agosti J. M., Waltersdorph A. M. Stimulation of neutrophils by tumor necrosis factor. J Immunol. 1986 Jun 1;136(11):4220–4225. [PubMed] [Google Scholar]
  14. Kramer S. M., Carver M. E. Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods. 1986 Nov 6;93(2):201–206. doi: 10.1016/0022-1759(86)90189-4. [DOI] [PubMed] [Google Scholar]
  15. Lenk H., Tanneberger S., Müller U., Ebert J., Shiga T. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1989;24(6):391–392. doi: 10.1007/BF00257449. [DOI] [PubMed] [Google Scholar]
  16. Lewis M., Tartaglia L. A., Lee A., Bennett G. L., Rice G. C., Wong G. H., Chen E. Y., Goeddel D. V. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2830–2834. doi: 10.1073/pnas.88.7.2830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pennica D., Nedwin G. E., Hayflick J. S., Seeburg P. H., Derynck R., Palladino M. A., Kohr W. J., Aggarwal B. B., Goeddel D. V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984 Dec 20;312(5996):724–729. doi: 10.1038/312724a0. [DOI] [PubMed] [Google Scholar]
  18. Pober J. S. TNF as an activator of vascular endothelium. Ann Inst Pasteur Immunol. 1988 May-Jun;139(3):317–323. doi: 10.1016/0769-2625(88)90149-3. [DOI] [PubMed] [Google Scholar]
  19. Shirai T., Yamaguchi H., Ito H., Todd C. W., Wallace R. B. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. 1985 Feb 28-Mar 6Nature. 313(6005):803–806. doi: 10.1038/313803a0. [DOI] [PubMed] [Google Scholar]
  20. Smith R. A., Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem. 1987 May 25;262(15):6951–6954. [PubMed] [Google Scholar]
  21. Soma G., Tsuji Y., Tanabe Y., Noguchi K., Kitahara-Tanabe N., Gatanaga T., Inagawa H., Kawakami M., Mizuno D. Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells. J Biol Response Mod. 1988 Dec;7(6):587–595. [PubMed] [Google Scholar]
  22. Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985 Nov 22;230(4728):943–945. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  23. Tsujimoto M., Tanaka S., Sakuragawa Y., Tsuruoka N., Funakoshi K., Butsugan T., Nakazato H., Nishihara T., Noguchi T., Vilcek J. Comparative studies of the biological activities of human tumor necrosis factor and its derivatives. J Biochem. 1987 Apr;101(4):919–925. doi: 10.1093/oxfordjournals.jbchem.a121960. [DOI] [PubMed] [Google Scholar]
  24. Vilcek J., Palombella V. J., Henriksen-DeStefano D., Swenson C., Feinman R., Hirai M., Tsujimoto M. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med. 1986 Mar 1;163(3):632–643. doi: 10.1084/jem.163.3.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yamagishi J., Kawashima H., Matsuo N., Ohue M., Yamayoshi M., Fukui T., Kotani H., Furuta R., Nakano K., Yamada M. Mutational analysis of structure--activity relationships in human tumor necrosis factor-alpha. Protein Eng. 1990 Aug;3(8):713–719. doi: 10.1093/protein/3.8.713. [DOI] [PubMed] [Google Scholar]